NAD+ and Migraines: What the Evidence Actually Supports

Written by the Nuvirox Research Team

Short answer: there's a genuine physiological rationale connecting NAD+ to migraine, but the human evidence is limited to case reports and small pilot observations of intravenous or intranasal NAD+ — not the randomized, placebo-controlled trials of oral NAD+ precursors that would let anyone make a confident claim. If you landed here because migraines are wrecking your week, the honest picture is this: NAD+ metabolism is plausibly involved in migraine biology, some clinics report improvement with IV infusions, but nothing has been tested in a proper trial using an oral NR or NMN capsule. Below is what's actually been published, not what's been marketed.

Why would NAD+ have anything to do with migraines?

Migraine involves waves of neuronal hyperexcitability, apparent mitochondrial energy deficits in the brain between attacks, and inflammatory signaling around the trigeminal nerve. NAD+ sits at the center of mitochondrial ATP production and is a required co-substrate for enzymes like PARPs and sirtuins that respond to cellular stress. The theoretical chain is straightforward: some migraine research has pointed to impaired energy metabolism in the migraine brain, and NAD+ depletion is one plausible contributor to that impairment. That's a mechanistic story worth taking seriously — but it is not proof that raising NAD+ levels changes migraine frequency or severity in people.

What has actually been tested in humans?

The clearest published human data comes from case reports out of NAD Research, Inc., a Louisiana-based clinical group that has documented patients receiving intranasal NAD+ (branded Brain Restoration Plus NAD+) for migraine pain. One widely cited case report describes an 87-year-old woman with chronic migraine who reported rapid, sustained relief after intranasal NAD+ administration, with a reduced need for rescue medication. A related case report from the same group describes a patient with both migraine and anxiety symptoms who showed similar improvement on the same protocol, with the authors noting reduced medication use and improved quality-of-life measures.

Separately, some IV therapy clinics describe small, unpublished pilot observations suggesting intravenous NAD+ infusions may reduce headache severity and duration in people with treatment-resistant chronic migraine. These are clinic-level observations shared through patient education materials, not peer-reviewed randomized trials, and they use intravenous or intranasal NAD+ directly — not an oral NR or NMN precursor capsule of the kind found in most supplements, including this one.

Why the difference between a case report and a randomized trial matters here

A case report tells you what happened to one or two people under a clinician's care. It cannot rule out placebo response, natural fluctuation in migraine frequency (migraine attacks vary a lot on their own, with or without treatment), or reporting bias from clinicians invested in their own protocol. A randomized, placebo-controlled trial is designed specifically to rule those things out by comparing outcomes to a matched control group receiving a look-alike placebo. For NAD+ and migraine specifically, no randomized controlled trial of an oral NAD+ precursor has been published as of this writing. That's a genuine gap, not a technicality — it's the difference between "a couple of patients felt better" and "this measurably outperforms placebo in a controlled comparison."

It's also worth being honest about the counterweight from adjacent research: a 2025 randomized, placebo-controlled trial of nicotinamide riboside (2000 mg/day for 20 weeks) in people with long-COVID found no significant between-group improvement in a range of symptom measures compared to placebo, despite NAD+ levels rising substantially in the treatment group. That trial wasn't about migraine, but it's a useful reminder that raising NAD+ levels doesn't automatically translate into symptom relief for a given condition — the connection has to be tested directly, condition by condition.

What does have strong evidence for migraine?

If migraine prevention is the actual goal, several options have real randomized trial support behind them: CGRP-targeting medications (a newer drug class specifically developed for migraine), certain blood pressure medications like propranolol, certain antidepressants like amitriptyline, magnesium supplementation in some populations, and riboflavin (vitamin B2) at doses around 400 mg/day. These aren't as novel or marketable as an NAD+ story, but the trial evidence behind them is considerably deeper.

What NAD+ won't do for migraines

NAD+ is not a migraine treatment, and nothing here should be read as a substitute for evidence-based migraine care. If you're having migraines with any new neurological symptoms — weakness, vision loss, confusion, or the worst headache of your life — that needs urgent medical evaluation, not a supplement. If migraines are frequent or disabling, a neurologist can build an actual evidence-based prevention plan tailored to your history, which is a very different conversation than what any general-wellness supplement can offer.

Is there a dose that makes sense to try?

Because no oral NAD+ precursor trial exists for migraine specifically, there's no evidence-based dose to point to for this particular use. The case reports use intranasal or IV NAD+, delivered in a clinical setting, at doses and protocols that aren't standardized or fully published. If you're already taking an NAD+ precursor supplement like NR for general cellular health reasons, there's no basis to expect it will change migraine frequency — the delivery route and the magnitude of NAD+ increase achieved with an oral capsule are different from what's described in the case reports.

Frequently asked questions

Does NAD+ IV therapy help migraines?

Some clinics report patient improvement with IV NAD+ for chronic migraine, described in case reports and internal pilot observations, but this hasn't been tested in a published randomized trial. It's reasonable to be curious, but the current evidence doesn't support a confident claim either way.

Is oral NAD+ the same as IV NAD+ for migraine purposes?

No. NAD+ itself is not well absorbed intact when taken orally; oral supplements typically use precursors like nicotinamide riboside that raise NAD+ gradually over days to weeks. IV and intranasal protocols deliver NAD+ (or push precursor levels) far more directly and quickly. The case report evidence is specific to that route, so it doesn't transfer to an oral capsule.

What actually has strong evidence for migraine prevention?

CGRP inhibitors, certain blood pressure medications, certain antidepressants, magnesium in some populations, and riboflavin all have randomized trial support for migraine prevention — worth discussing with a doctor before trying something with a thinner evidence base.

Can migraines be a sign of something more serious?

Most migraines aren't dangerous, but a sudden, unusually severe headache, or one with fever, stiff neck, confusion, weakness, or vision loss warrants immediate medical attention, since these can signal other conditions.

The bottom line

NAD+ has a plausible biological connection to migraine through mitochondrial energy metabolism, and a handful of case reports describe patients improving with intravenous or intranasal NAD+ under clinical supervision. But "plausible mechanism plus a couple of case reports" is a long way from "proven treatment," and no randomized trial of an oral NAD+ precursor for migraine exists. If migraines are a real problem for you, the better first move is an evidence-based conversation with a doctor or neurologist about the options that do have trial support — and to treat any NAD+ supplement as general cellular-health support, not a headache treatment. You can read more about our approach to NAD+ and stress resilience and whether NAD+ functions as a nootropic for related context on the brain-health evidence base.

References

1. White J, Podesta A, Dyess GA, Broom SL, Mestayer RF. Intranasal administration of nicotinamide adenine dinucleotide alleviates headaches associated with migraine pain: a case report. NAD Research, Inc. Available at: nadresearch.org.
2. White J, Podesta A, Dyess GA, Broom SL, Mestayer RF. IN NAD, migraine headaches and anxiety disorders: a case report. NAD Research, Inc. Available at: nadresearch.org.
3. Wu CY, Reynolds WC, Abril I, et al. Effects of nicotinamide riboside on NAD+ levels, cognition, and symptom recovery in long-COVID: a randomized controlled trial. eClinicalMedicine. 2025. PMID: 41357333.
4. Rajapakse T, Pringsheim T. Nutraceuticals in migraine: a summary of existing guidelines for use. Headache. 2016;56(4):808-816. PMID: 27015869.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.